Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

A prospective study of fe… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment

Artikel i vetenskaplig tidskrift
Författare Eva Smith Knutsson
Yvonne Björk
A. K. Broman
L. Helstrom
Malin Nicklasson
Mats Brune
Karin Sundfeldt
Publicerad i Acta Obstetricia Et Gynecologica Scandinavica
Volym 97
Nummer/häfte 9
Sidor 1122-1129
ISSN 0001-6349
Publiceringsår 2018
Publicerad vid Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition
Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi
Sidor 1122-1129
Språk en
Länkar dx.doi.org/10.1111/aogs.13366
Ämnesord Allogeneic hematopoietic stem cell transplantation, chronic graft-versus-host disease, diagnostic, bone-marrow-transplantation, stem-cell transplantation, consensus, development project, working group-report, clinical-trials, management, tacrolimus, survivors, criteria, Obstetrics & Gynecology
Ämneskategorier Reproduktionsmedicin och gynekologi, Invärtesmedicin

Sammanfattning

IntroductionFemale genital chronic graft-versus-host disease (cGvHD) is a complication of allogeneic hematopoietic cell transplantation (alloHCT) for blood malignancies. Unattended inflammation and fibrosis in the vulva andvagina may lead to total vaginal stenosis. The course and treatment of genital cGvHD was observed in this population-based prospective study. Material and methodsWomen (n=41) receiving alloHCT in 2005-10 were examined before and at 3, 6, 9, 12, 18, 24, 30 and 36months post-transplant. Vulvovaginal signs were documented, National Institutes of Health clinical scores were calculated, and women completed questionnaires on symptoms, the Female Sexual Distress Scale and the Beck Depression Inventory. Local immunosuppressive treatment was given weekly. ResultsGenital cGvHD was diagnosed in 27 women (incidence 56% at 12months; 66% at 36months); extragenital cGvHD was found in 21/27. The most common signs at diagnosis were red and white spots, reticular white lines, fissures, synechiae and telangiectasia; symptoms included dryness, itching, dyspareunia, pain or no symptoms. Thirteen women were treated on a schedule of tacrolimus and clobetazol ointments. Although some signs progressed during treatment, only two women developed total stenosis. At 36months, 12 women still had genital cGvHD. ConclusionsGenital cGvHD develops mainly in the first year after alloHCT. Early intervention may halt its progress to severe fibrosis, but despite correct diagnosis and treatment, symptoms and signs may become chronic. Women who develop genital cGvHD following alloHCT require life-long gynecological supervison and care.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?